From Lab to Clinic: Nudge Zero Enters Human Trials Following $100M Raise

Nudge, a pioneering neurotech startup building non-invasive, focused ultrasound brain interfaces , has secured a $100 million Series A round led by Thrive Capital and Greenoaks . This milestone positions the company for aggressive technology advancement and clinical growth.

Founded with the mission to address neurological and psychiatric disorders such as chronic pain, PTSD, Alzheimer’s, and addiction—affecting nearly 1 billion people globally —Nudge’s first human-ready system, “Nudge Zero” , enables deep-brain stimulation with millimeter precision , without surgery. It has already entered daily-use research in clinical trials.

By vertically integrating hardware, software, and neuroscience, Nudge aims to deliver a scalable, adaptive, and safe platform to modulate brain circuits. Its bespoke ultrasound hardware, physics-based modeling, real-time personalization, and signal processing stack enable this high-fidelity interaction across patients.

The fresh capital will accelerate commercialization of Nudge Zero, expansion into therapeutic research, and development of consumer brain interface applications. The team comprises world-class engineers, neuroscientists, and clinical ops professionals, backed by a roadmap targeting safe, non-invasive brain therapies for everyday use.

Source: Nudge

M.A.